Indication
The EMA label of Aimovig ® states approval for patients with at least 4 monthly migraine days.
Although the reimbursement criteria in Belgium are more limited, Aimovig ® is indicated for patients with at least 8 monthly...
The EMA label of Aimovig ® states approval for patients with at least 4 monthly migraine days.
Although the reimbursement criteria in Belgium are more limited, Aimovig ® is indicated for patients with at least 8 monthly...